Results 91 to 100 of about 115,048 (305)

Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States. [PDF]

, 2017
BACKGROUND: Median age at diagnosis of patients with chronic lymphocytic leukemia (CLL) is \u3e 70 years. However, the majority of clinical trials do not reflect the demographics of CLL patients treated in the community.
Bhushan, Shriya, Davids, Matthew S., Flick, E. Dawn, Flowers, Christopher R., Grinblatt, David L., Kiselev, Pavel, Lamanna, Nicole, Mato, Anthony, Nabhan, Chadi, Sharman, Jeff P., Sullivan, Kristen, Swern, Arlene S., Weiss, Mark A.   +12 more
core   +3 more sources

Dual‐Targeting Cuproptosis and Mitophagy via a Flavopiridol‐Copper Nanoplatform Potentiates Immunotherapy Against Uveal Melanoma

Advanced Science, EarlyView.
This study develops a GSH‐responsive nanoplatform, NP@Fla‐Cu, to co‐activate cuproptosis and excessive mitophagy in uveal melanoma. The nanoplatform enhances tumor‐specific copper delivery, depletes antioxidant defenses, and remodels the tumor immune microenvironment.
Hong Ren, Zhihong Deng, Sheng Lu, Jing Zhang, Wenbin Liu, Jia Tan   +5 more
wiley   +1 more source

Coexistence of chronic lymphocytic leukemia and polycythemia vera: a case report and review of the literature

Annals of Saudi Medicine, 2016
Polycythemia vera is a Philadelphia chromosome-negative myeloproliferative neoplasm. Chronic lymphocytic leukemia is a monoclonal expansion of a CD5+ CD19+ B lymphocytes.
Serdal Korkmaz, Sinan Kulakoglu, Hasan Gorkem, Bilal Aygun, Ali Cetinkaya   +4 more
doaj   +1 more source

Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. [PDF]

, 2018
Not ...
Bomben, R, Bonina, S, Cafforio, L, Cappelli, Lv, Cuneo, A, Dal Bo, M, Del Giudice, I, Del Poeta, G, Diop, F, Favini, C, Foá, R., Gaidano, G, Gattei, V, Guarini, A, Ilari, C, Mariglia, P, Marinelli, M, Mauro, Fr, Messina, M, Peragine, N, Piciocchi, A, Raponi, S, Rigolin, Gm, Rossi, D, Rossi, F   +24 more
core   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source

Doxorubicin has a synergistic cytotoxicity with cucurbitacin B in anaplastic thyroid carcinoma cells

Tumor Biology, 2017
In this study, the combined effect of doxorubicin with cucurbitacin B on survival of anaplastic thyroid carcinoma cells was evaluated. For experiments, 8505C and CAL62 human anaplastic thyroid carcinoma cells were used.
Si Hyoung Kim, Jun Goo Kang, Chul Sik Kim, Sung-Hee Ihm, Moon Gi Choi, Hyung Joon Yoo, Seong Jin Lee   +6 more
doaj   +1 more source

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani, Alam, Ashino, Baba, Bendall, Billottet, Burger, Burger, Byrd, Chang, Cordle, Dasmahapatra, David J. MacEwan, de Weers, Dos Santos, Doyle, Fiedler, Gallay, Grandage, Gu, Guzman, Hahn, Herman, Herrmann, Honda, Honigberg, Horwood, Ishii, Juliusson, Kawakami, Kim, Kojima, Kristian M. Bowles, Kvinlaug, Lyubov Zaitseva, Megan Y. Murray, Min, Mohamed, Nanri, Park, Quek, Renneville, Rushworth, Rushworth, Rushworth, Shinners, Sivina, Spiekermann, Stuart A. Rushworth, Sujobert, Tai, Tamburini, Tomasson, Tsukada, Vellenga, Venkataraman, Vetrie, Welch, Westermann, Zaitseva   +59 more
core   +1 more source

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

Advanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun, Qihong Li, Bixi Wang, Gang Wang, Ying Xue, Yibing Liang, Chenhe Hu, Zhenyu Wang, Xiaoge Gao, Haiheng Xu, Jun Song, Hailong Li, Liantao Li, Xiaoxiao Liu, Patrick Ming‐Kuen Tang, Qing Zhang   +15 more
wiley   +1 more source

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. [PDF]

, 2019
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or ...
Bairey, Osnat, Barr, Paul M., Burger, Jan A., Coutre, Steven E., Dai, Sandra, Dean, James P., Devereux, Stephen, Ghia, P, Grosicki, Sebastian, Hillmen, Peter, Kipps, Thomas J., Lal, Indu, McCarthy, Helen, Moreno, Carol, Offner, Fritz, Owen, Carolyn, Robak, Tadeusz, Simpson, David, Tedeschi, Alessandra, Universitat Autònoma de Barcelona   +19 more
core   +3 more sources

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source